Profile data is unavailable for this security.
About the company
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
- Revenue in EUR (TTM)3.04m
- Net income in EUR-26.18m
- Incorporated2017
- Employees114.00
- LocationHeidelberg Pharma AGSchriesheimer Strasse 101LADENBURG 68526GermanyDEU
- Phone+49 620310090
- Fax+49 6 203100919
- Websitehttps://www.heidelberg-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope Fluidics SA | 167.33k | 12.69m | 106.47m | 132.00 | 7.21 | 3.41 | 8.09 | 636.30 | 19.99 | 19.99 | 0.2633 | 42.35 | 0.0065 | 0.9348 | 10.80 | 11,396.83 | 49.25 | 54.44 | 52.79 | 58.98 | -178.69 | -440.53 | 7,586.77 | 33,272.12 | 12.82 | -- | 0.0212 | -- | -74.61 | -- | 448.26 | -- | 5.75 | -- |
| Abionyx Pharma SA | 4.33m | -4.60m | 112.22m | 51.00 | -- | 19.97 | -- | 25.94 | -0.1317 | -0.1317 | 0.1238 | 0.1582 | 0.3033 | 17.39 | 7.16 | 84,823.53 | -32.25 | -26.53 | -43.11 | -38.31 | 17.78 | 15.59 | -106.31 | -131.06 | 1.35 | -- | 0.4281 | -- | -1.92 | -- | -24.53 | -- | -- | -- |
| Adocia SA | 10.35m | -9.71m | 121.96m | 77.00 | -- | -- | -- | 11.78 | -0.5622 | -0.5622 | 0.6343 | -0.0338 | 0.4068 | -- | 2.55 | 134,428.60 | -38.16 | -47.62 | -184.08 | -104.50 | -- | -- | -93.83 | -331.17 | 1.12 | -14.58 | 1.06 | -- | 333.49 | 34.18 | 55.95 | -- | -35.29 | -- |
| MindMaze Therapeutics Holding SA | 4.46m | -18.76m | 122.47m | 31.00 | -- | 0.2694 | -- | 27.43 | -1.36 | -1.36 | 0.3231 | 2.59 | 0.0682 | 2.49 | 2.75 | 130,774.20 | -28.66 | -33.04 | -30.87 | -35.76 | 60.24 | -- | -420.33 | -874.66 | 3.80 | -49.62 | 0.055 | -- | 39.52 | -- | 82.56 | -- | -- | -- |
| Nightingale Health Oyj | 4.69m | -18.46m | 123.08m | 100.00 | -- | 1.32 | -- | 26.23 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 123.59k | -11.52m | 125.36m | 56.00 | -- | 9.01 | -- | 1,014.34 | -0.4666 | -0.4666 | 0.005 | 0.4654 | 0.0032 | -- | 0.0153 | 2,206.96 | -29.50 | -- | -35.51 | -- | 3,682.88 | -- | -9,319.20 | -- | -- | -9.31 | 0.5944 | -- | 560.26 | -- | -4.50 | -- | -- | -- |
| Maat Pharma SA | 3.92m | -31.13m | 128.00m | 60.00 | -- | 13.23 | -- | 32.64 | -2.15 | -2.15 | 0.270 | 0.5141 | 0.0786 | 11.22 | 0.5785 | 65,366.67 | -62.39 | -41.51 | -90.20 | -51.87 | 61.68 | -- | -793.83 | -976.99 | 2.21 | -29.53 | 0.6346 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Innate Pharma SA | 6.00m | -46.05m | 128.05m | 181.00 | -- | 24.47 | -- | 21.34 | -0.5497 | -0.5497 | 0.0714 | 0.0558 | 0.0491 | -- | 15.81 | 33,149.17 | -37.68 | -13.19 | -52.10 | -17.17 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.8401 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Thor Medical ASA | 44.51k | -5.16m | 131.44m | 13.00 | -- | 3.24 | -- | 2,953.00 | -0.1803 | -0.1803 | 0.0015 | 1.29 | 0.0009 | -- | 0.0444 | -- | -10.35 | -32.89 | -11.00 | -40.41 | -- | -- | -11,620.00 | -136,767.80 | 4.50 | -- | 0.2732 | -- | -- | -- | -37.41 | -- | 230.64 | -- |
| BioInvent International AB | 21.04m | -30.93m | 132.07m | 109.00 | -- | 2.55 | -- | 6.28 | -5.05 | -5.05 | 3.44 | 8.47 | 0.2728 | -- | 11.07 | 2,077,936.00 | -40.09 | -22.49 | -45.82 | -24.02 | -- | -- | -146.96 | -205.40 | 5.56 | -- | 0.0151 | -- | 406.86 | 8.98 | 22.48 | -- | 1.62 | -- |
| Heidelberg Pharma AG | 3.04m | -26.18m | 132.87m | 114.00 | -- | 12.62 | -- | 43.74 | -0.558 | -0.558 | 0.0647 | 0.2251 | 0.0507 | 0.0329 | 69.14 | 28,928.10 | -43.69 | -40.90 | -50.29 | -58.51 | 84.66 | 55.95 | -861.83 | -228.64 | 3.55 | -- | 0.7766 | -- | -30.53 | -1.29 | 4.74 | -- | -13.09 | -- |
| Ryvu Therapeutics SA | 16.27m | -27.66m | 134.70m | 294.00 | -- | 8.12 | -- | 8.28 | -5.13 | -5.13 | 3.02 | 3.08 | 0.212 | 12.29 | 7.31 | 237,411.60 | -36.05 | -23.64 | -48.51 | -27.84 | 70.86 | 29.35 | -170.05 | -208.85 | 2.26 | -- | 0.572 | -- | 66.38 | 83.01 | -20.98 | -- | -24.46 | -- |
| Devyser Diagnostics AB | 23.28m | -780.48k | 135.39m | 116.00 | -- | 4.11 | 81.41 | 5.81 | -0.5142 | -0.5142 | 15.09 | 21.27 | 0.5312 | 1.45 | 4.65 | 2,160,345.00 | -1.95 | -8.59 | -2.30 | -9.76 | 80.61 | 81.08 | -3.67 | -22.20 | 2.36 | 0.6429 | 0.1278 | -- | 15.49 | 30.70 | 86.34 | -- | 83.06 | -- |
| Xlife Sciences AG | 924.34k | 33.87m | 137.19m | 17.00 | 5.30 | 0.4088 | 3.03 | 148.42 | 4.08 | 4.08 | 0.1284 | 52.84 | 0.0016 | -- | 0.0907 | 49,375.29 | 4.80 | 6.01 | 5.95 | 7.37 | 62.17 | 37.44 | 2,991.34 | 2,987.92 | 1.07 | -- | 0.131 | -- | -15.54 | 10.15 | 130.37 | 100.79 | -13.48 | -- |
| Intellego Technologies AB | 68.57m | 17.82m | 144.27m | 64.00 | 7.01 | 11.41 | 7.22 | 2.10 | 6.64 | 6.64 | 23.96 | 4.08 | 2.03 | 11.02 | 15.11 | 11,530,660.00 | 52.66 | -15.74 | 75.55 | -23.48 | 60.32 | 13.73 | 26.00 | -33.49 | 2.53 | 3.94 | 0.0642 | -- | 4.34 | 67.41 | -70,300.74 | -- | 36.08 | -- |
| Scancell Holdings Plc | 5.42m | -6.34m | 147.99m | 60.00 | -- | -- | -- | 27.32 | -0.0053 | -0.0053 | 0.0047 | -0.0081 | 0.2946 | -- | 8.26 | 78,516.66 | -34.46 | -33.29 | -- | -44.23 | 94.95 | -- | -116.98 | -502.03 | -- | -- | 2.07 | -- | -- | -- | -109.46 | -- | 124.48 | -- |
Data as of Mar 04 2026. Currency figures normalised to Heidelberg Pharma AG's reporting currency: Euro EUR
0.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baader Bank AG (Investment Management)as of 28 Nov 2025 | 331.97k | 0.71% |
| Universal Investment Luxembourg SAas of 28 Nov 2025 | 129.73k | 0.28% |
| Gutmann Finanz Strategien AGas of 31 Dec 2025 | 3.40k | 0.01% |
| Montpensier Arbevel SASas of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 28 Nov 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
